Scientists say your breathing pattern may reveal identity, mood, and health
In a groundbreaking study, scientists have found that each person's breathing pattern is distinct enough to serve as a kind of respiratory fingerprint.
Careful analysis of those patterns over a full day allowed researchers to identify individuals with nearly 96.8 percent accuracy, underscoring just how unique our breath really is.
The research originated from the lab's focus on olfaction — the sense of smell.
In mammals, the brain processes scent during inhalation, tying breathing closely to brain activity.
This connection sparked a question: if every brain is unique, could our breathing patterns reveal that individuality?
To test their hypothesis, the team designed a lightweight wearable device that continuously monitors nasal airflow, using soft, flexible tubes positioned just beneath the nostrils.
The team, led by brain scientist Timna Soroka at the Weizmann Institute of Science in Israel, discovered that our breath isn't just a mechanical reflex.
It's shaped by a complex neural network in the brain and subtly influenced by everything from physical activity to emotional state.
Discreet device on the nape of the neck, which recorded airflow through soft tubes connected to the nose. Credit-Soroka et al. Current Biology'You would think that breathing has been measured and analyzed in every way,' says author Noam Sobel of the Weizmann Institute of Science, Israel.
'Yet we stumbled upon a completely new way to look at respiration. We consider this as a brain readout.'
Using a device that fits neatly over the nose, the researchers monitored the breathing patterns of 100 healthy young adults as they went about their daily lives, capturing a detailed log of 24 respiratory parameters.
Even just an hour of recorded breathing allowed for moderate identification, but with a full day's worth of data, the uniqueness of each person's breath pattern became strikingly clear.
What's more, these breathing signatures didn't just point to identity. They also hinted at broader health markers, from body mass index, sleep-wake cycle, levels of depression and anxiety, and even behavioral traits.
Participants with self-reported anxiety, for instance, showed shorter inhales and greater variability during sleep, opening new avenues for mental health diagnostics through breath alone.
Researchers, however, noted that none of the participants met clinical diagnostic criteria for mental or behavioral conditions.
'We intuitively assume that how depressed or anxious you are changes the way you breathe,' says Sobel. 'But it might be the other way around. Perhaps the way you breathe makes you anxious or depressed. If that's true, we might be able to change the way you breathe to change those conditions.'
The current device still has practical hurdles to overcome. Its visible nasal tube can evoke associations with illness, potentially discouraging everyday use. It also doesn't track mouth breathing and can shift during sleep.
The team is now working on a more discreet, user-friendly design to make long-term wear more comfortable and appealing.
The researchers are already investigating whether people can mimic healthy breathing patterns to improve their mental and emotional states.
'We definitely want to go beyond diagnostics to treatment, and we are cautiously optimistic,' says Sobel.
This research has been published in Current Biology.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'We continue to execute across our clinical, commercial, and operational objectives,' said Ofer Gonen, Chief Executive Officer of MediWound. 'The VALUE Phase III trial of EscharEx® is actively recruiting patients, and with the addition of Convatec and Essity to our clinical partnerships, we are now collaborating with all relevant leading global wound care companies. In the U.S., NexoBrid® is gaining commercial traction, and our manufacturing expansion remains on track to meet the anticipated growth in demand. The solid progress in the first half of 2025 reinforces our confidence in our long-term strategy and our commitment to value creation. Second Quarter 2025 Highlights, Recent Developments, and Upcoming Milestones: EscharEx® Enrollment in the global VALUE Phase III study for the treatment of venous leg ulcers (VLUs) is ongoing. The trial aims to enroll 216 patients across 40 sites in the U.S. and Europe. Interim sample size assessment is planned for mid-2026, after 65% of patients complete treatment. Established new collaborations with Essity and Convatec to support EscharEx trials. The VALUE Phase III VLU trial now includes JOBST®, a leading medical compression therapy brand, while the planned DFU trial will incorporate AQUACEL®, a market-leading wound dressing. These partnerships complement the existing ones with Solventum, Mölnlycke, Kerecis, and MIMEDX, reflecting strong industry recognition of EscharEx's clinical value and potential. Published a post-hoc analysis of new data from the EscharEx Phase II trial in Advances in Wound Care, a peer-reviewed journal, providing clinical evidence that wound bed preparation is a key predictor of healing in venous leg ulcers. NexoBrid® U.S. adoption continues to grow. Vericel, MediWound's exclusive U.S. commercial partner, reported 52% year-over-year revenue growth for NexoBrid in the second quarter, supported by increases in both hospital unit orders and the number of ordering centers. Commissioning of MediWound's expanded manufacturing facility—engineered to increase NexoBrid production capacity six-fold—remains on track, with full operational readiness anticipated by year-end 2025. Regulatory review will determine commercial availability timelines. As part of a BARDA-funded initiative, planning continues for future U.S.-based manufacturing to support global demand. Received an additional $3.6 million in funding from the U.S. Department of Defense (DoD) to advance development of a room temperature-stable formulation of NexoBrid. The supplemental funding will support expanded CMC activities, enhancement of in-house manufacturing capabilities, and initial preparations for a clinical trial. Second Quarter 2025 Financial Highlights Revenue for the second quarter of 2025 increased to $5.7 million, compared to $5.1 million in the same period of 2024. Gross profit totaled $1.3 million, or 23.5% of total revenue, compared to $0.4 million, or 8.8% of total revenue, in the prior-year period. The margin improvement reflects a more favorable revenue mix. Research and development expenses were $3.5 million, compared to $1.9 million a year ago, driven by increased investment in the EscharEx VALUE Phase III trial and related clinical activities. Selling, general and administrative expenses were $3.6 million, compared to $3.0 million in the second quarter of 2024, primarily due to higher share-based compensation expenses. Operating loss was $5.7 million, compared to $4.5 million in the same period last year. Net loss was $13.3 million, or $1.23 per share, compared to $6.3 million, or $0.68 per share, in the second quarter of 2024. The year-over-year increase was primarily driven by $6.6 million in non-cash financial expenses in the second quarter of 2025, related to the revaluation of warrants. Non-GAAP Adjusted EBITDA loss was $4.5 million, compared to a loss of $3.4 million in the prior-year quarter. Year-to-Date 2025 Financial Highlights Revenue for the first half of 2025 was $9.7 million, compared to $10.0 million in the same period of 2024. The decrease primarily reflects lower BARDA-funded development services revenue as NexoBrid development nears completion. Gross profit totaled $2.1 million, or 21.5% of total revenue, compared to $1.1 million, or 10.5% of total revenue, in the first half of 2024. The margin improvement reflects a more favorable revenue mix. Research and development expenses were $6.4 million, compared to $3.4 million in the same period of 2024, reflecting increased investment in the EscharEx VALUE Phase III trial and related clinical activities. Selling, general and administrative expenses were $6.6 million, compared to $5.9 million in the first half of 2024, primarily due to higher share-based compensation expenses. Operating loss was $10.9 million, compared to $8.2 million in the same period of 2024. Net loss was $14.0 million, or $1.30 per share, compared to $16.0 million, or $1.73 per share, in the first half of 2024. Non-GAAP Adjusted EBITDA loss was $8.5 million, compared to a loss of $6.2 million in the same period of 2024. Balance Sheet Highlights As of June 30, 2025, MediWound had cash, cash equivalents, and short-term deposits of $32.9 million, compared to $43.6 million as of December 31, 2024. During the first half of 2025, the Company used $11.9 million to fund operations, including $2.3 million in capital expenditures primarily related to manufacturing scale-up. MediWound received $0.7 million in proceeds from the exercise of Series A warrants during the quarter, with an additional $1.8 million received after quarter-end. Conference Call and Webcast MediWound management will host a conference call for investors on Thursday, August 14, 2025, beginning at 8:30 a.m., Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-844-676-8833 (in the U.S.), 1-80-921-2373 (Israel), or 1-412-634-6869 (outside the U.S. & Israel). The call will be available via webcast by clicking HERE or on the Events & Presentations page of Company's website. A replay of the call will be available on the Company's website at Non-IFRS Financial Measures To supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure to consider in evaluating the Company's performance. Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization, impairment, one-time expenses, restructuring and share-based compensation expenses. Although Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with IFRS, we believe the non-IFRS financial measures we present provide meaningful supplemental information regarding our operating results primarily because they exclude certain non-cash charges or items that we do not believe are reflective of our ongoing operating results when budgeting, planning and forecasting and determining compensation, and when assessing the performance of our business with our senior management. However, investors should not consider these measures in isolation or as substitutes for operating income, cash flows from operating activities or any other measure for determining the Company's operating performance or liquidity that is calculated in accordance with IFRS. In addition, because Adjusted EBITDA is not calculated in accordance with IFRS, it may not necessarily be comparable to similarly titled measures employed by other companies. The non-IFRS measures included in this press release have been reconciled to the IFRS results in the tables below. About MediWound MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company's FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity. For more information visit and follow us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as 'anticipates,' 'intends,' 'estimates,' 'plans,' 'expects,' 'continues,' 'believe,' 'guidance,' 'outlook,' 'target,' 'future,' 'potential,' 'goals' and similar words or phrases, or future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' 'may,' or similar expressions. Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates, including EscharEx® and NexoBrid®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 19, 2025 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law. MediWound Contacts: Media Contact: Hani Luxenburg Daniel Ferry Ellie Hanson Chief Financial Officer Managing Director FINN Partners for MediWound MediWound Ltd. LifeSci Advisors, LLC ir@ daniel@ +1-929-588-2008MediWound, Condensed Consolidated Statements of Financial PositionU.S. dollars in thousands June 30, December 31, 2025 2024 2024 Cash and cash equivalents and short-term deposits 32,436 29,215 43,161 Trade and other receivable 6,800 4,888 6,310 Inventories 3,843 3,210 2,692 Total current assets 43,079 37,313 52,163 Other receivables and long-term restricted bank deposits 490 691 439 Property, plant and equipment 15,724 12,308 14,132 Right of use assets 7,642 6,852 6,663 Intangible assets 66 132 99 Total non-current assets 23,922 19,983 21,333 Total assets 67,001 57,296 73,496 Current maturities of long-term liabilities 822 1,496 612 Warrants 18,992 14,902 17,092 Trade payables and accrued expenses 5,880 2,745 5,281 Other payables 3,377 3,468 3,556 Total current liabilities 29,071 22,611 26,541 Grants received in advance 758 - 736 Liabilities in respect of IIA grants 8,504 8,009 8,149 Liabilities in respect of TEVA - 1,962 - Lease liabilities 8,070 6,355 6,513 Severance pay liability, net 479 490 404 Total non-current liabilities 17,811 16,816 15,802 Total liabilities 46,882 39,427 42,343 Shareholders' equity 20,119 17,869 31,153 Total liabilities and equity 67,001 57,296 73,496MediWound, Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income or LossU.S. dollars in thousands (except of share and per share data) Six months ended Three months ended Year ended June 30, June 30, December 31, 2025 2024 2025 2024 2024 Total revenues 9,663 10,027 5,708 5,063 20,222 Cost of revenues 7,583 8,973 4,366 4,616 17,588 Gross profit 2,080 1,054 1,342 447 2,634 Research and development 6,377 3,368 3,491 1,898 8,878 Selling and marketing 2,749 2,403 1,462 1,224 4,936 General and administrative 3,891 3,501 2,105 1,809 8,202 Other expenses 4 - - - 18 Operating loss (10,941) (8,218) (5,716) (4,484) (19,400) Financing expenses, net (3,060) (7,794) (7,564) (1,823) (10,763) Taxes on income (43) (22) (38) 2 (61) Net loss (14,044) (16,034) (13,318) (6,305) (30,224) Foreign currency translation adjustments (10) 10 (11) 2 7 Total comprehensive loss (14,054) (16,024) (13,329) (6,303) (30,217) Basic and diluted net loss per share (1.30) (1.73) (1.23) (0.68) (3.03) Number of shares used in calculating basic and diluted loss per share 10,816,990 9,256,862 10,835,251 9,279,370 9,959,723 MediWound Condensed Consolidated Statements of Cash FlowsU.S. dollars in thousands Six months ended Three months ended Year Ended June 30, June 30, December 31, 2025 2024 2025 2024 2024 Cash flows from operating activities: Net loss (14,044 ) (16,034 ) (13,318 ) (6,305 ) (30,224 ) Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to profit and loss items: Depreciation and amortization 752 725 394 357 1,483 Share-based compensation 1,706 1,270 862 758 3,138 Revaluation of warrants accounted at fair value 2,377 8,007 6,647 1,927 10,704 Revaluation of liabilities in respect of IIA grants 446 470 203 237 752 Revaluation of liabilities in respect of TEVA - 206 - 99 770 Financing (income) expenses and exchange differences of lease liability 943 17 938 (11 ) 487 Increase (decrease) in severance pay liability, net 75 48 48 13 (30 ) Other expenses 4 - - - 18 Financial income, net (942 ) (918 ) (424 ) (405 ) (2,039 ) Unrealized foreign currency loss (gain) (21 ) 78 (6 ) 11 47 5,340 9,903 8,662 2,986 15,330 Changes in asset and liability items: Decrease (increase) in trade receivables (217 ) 753 (1,671 ) 876 (1,141 ) Decrease (increase) in inventories (1,151 ) (345 ) (263 ) 103 187 Decrease (increase) in other receivables (341 ) (574 ) 37 (459 ) 120 Increase (decrease) in trade payables and accrued expenses 691 (1,900 ) 794 (530 ) 406 Increase in grants received in advance - - - - 1,181 Increase (decrease) in other payables (144 ) (34 ) 3 (294 ) 517 (1,162 ) (2,100 ) (1,100 ) (304 ) 1,270 Net cash used in operating activities (9,866 ) (8,231 ) (5,756 ) (3,623 ) (13,624 )MediWound Condensed Consolidated Statements of Cash FlowsU.S. dollars in thousands Six months ended Three months ended Year Ended June 30, June 30, December 31, 2025 2024 2025 2024 2024 Cash flows from investing activities: Purchase of property and equipment (2,008 ) (4,275 ) (1,049 ) (3,016 ) (6,273 ) Interest received 585 1,127 319 522 2,252 Proceeds from (investment in) short-term bank deposits, net 2,985 4,209 5,635 5,339 (4,376 ) Net cash provided by (used in) investing activities 1,562 1,061 4,905 2,845 (8,397 ) Cash flows from financing activities: Repayment of leases liabilities (537 ) (458 ) (289 ) (214 ) (928 ) Proceeds from exercise of warrants and share options 838 610 838 111 1,210 Proceeds from issuance of shares - - - - 22,165 Repayment of IIA grants (114 ) (120 ) - - (219 ) Repayment of liabilities in respect of TEVA - (834 ) - - (2,834 ) Net cash provided by (used in) financing activities 187 (802 ) 549 (103 ) 19,394 Exchange rate differences on cash and cash equivalent balances 21 (104 ) 2 (15 ) (84 ) Decrease in cash and cash equivalents (8,096 ) (8,076 ) (300 ) (896 ) (2,711 ) Balance of cash and cash equivalents at the beginning of the period 9,155 11,866 1,359 4,686 11,866 Balance of cash and cash equivalents at the end of the period 1,059 3,790 1,059 3,790 9,155 MediWound EBITDAU.S. dollars in thousands Six months ended Three months ended Year Ended June 30, June 30, December 31, 2025 2024 2025 2024 2024 Net loss (14,044 ) (16,034 ) (13,318 ) (6,305 ) (30,224 ) Adjustments: Financing expenses, net (3,060 ) (7,794 ) (7,564 ) (1,823 ) (10,763 ) Other expenses, net (4 ) - - - (18 ) Taxes on income (43 ) (22 ) (38 ) 2 (61 ) Depreciation and amortization (752 ) (725 ) (394 ) (357 ) (1,483 ) Share-based compensation expenses (1,706 ) (1,270 ) (862 ) (758 ) (3,138 ) Total adjustments (5,565 ) (9,811 ) (8,858 ) (2,936 ) (15,463 ) Adjusted EBITDA (8,479 ) (6,223 ) (4,460 ) (3,369 ) (14,761 )Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
an hour ago
- Forbes
The Neuroscience Behind Why Emotional Intelligence Training Fails
Sahar Andrade, a neuroscience-based leadership expert& executive coach who rewires brains for peak performance& authentic human connection. While in a session, I asked the attending leaders, "How many of you have had empathy training?" Thirty-seven hands shot up across the leadership team. "Great. What's the first cornerstone of emotional intelligence?" Crickets. Not one hand. These were seasoned executives who could recite the importance of understanding their teams' feelings, but they couldn't name the foundation: self-awareness. We've been teaching leaders to be emotional lifeguards who can't swim. The Mirror Neuron Trap When you encounter someone else's distress, specialized cells in your brain called 'mirror neurons' fire as if you're experiencing that emotion yourself. This neural mirroring helped our ancestors survive by quickly reading danger and coordinating group responses. Sarah, a VP I coached, absorbed every piece of empathy training her company offered and was having panic attacks in bathroom stalls. "I feel everything they feel," she told me, exhausted. "When John's stressed about his deadline, I'm stressed. I can't turn it off." Sarah had become an emotional sponge. Neuroscience shows why: Without proper regulation, mirror neurons become mirror traps, reflecting every anxiety into your limbic system. The Cortisol Catastrophe When you absorb stress from others, your hypothalamic-pituitary-adrenal axis doesn't distinguish between your crisis and theirs. It floods your system with cortisol, your brain's worst enemy. Cortisol is like someone hitting the brakes on your car while you're flooring the gas pedal. No matter how hard you press that empathy accelerator, your brain won't move an inch. It floods the system, taking longer to clear and become operational again. Chronic cortisol exposure shrinks the prefrontal cortex, responsible for decision-making and authentic empathy, while enlarging the amygdala, making you hypersensitive to every emotional stimulus, constantly scanning for the next crisis to absorb. The Compassion Versus Empathy Distinction Research from the Max Planck Society reveals a crucial difference between empathy and compassion. Empathy, feeling what others feel—activates pain networks and leads to "empathic distress." Compassion activates entirely different neural networks associated with care and positive motivation. The difference is profound: Empathy says, "I feel your pain." Compassion says, "I see your pain, and I'm here to help." One creates two victims. The other creates a solution. The Interoceptive Intelligence Gap Most leadership development ignores interoception, sensing what's happening inside your body. Heart rate. Breathing. Shoulder tension. These aren't just physical sensations; they're emotional data streams. When leaders lack this awareness, they can't distinguish between their emotional state and their team's. Your vagus nerve constantly communicates between brain and body, regulating heart rate and social engagement. Being aware of these signals, you can consciously influence your nervous system state. When you're not? Your biology drives your behavior unconsciously. The Artificial Harmony That Employees Detect The brutal truth: Your employees know when empathy is performed. Generation-Z especially has radar for authenticity. When a leader mirrors emotions without genuine self-regulation, it creates "artificial harmony' corporate emotional theater that nobody believes. A dysregulated nervous system trying to calm others is like a drowning person trying to save another drowning person. Good intentions; devastating results. The Self-Awareness Solution "This sounds selfish," executives push back. "Shouldn't leaders put people first?" Here's the paradox: Taking care of yourself is putting people first. You literally can't give what you don't have. When you're grounded, you serve your team more effectively. You're ready, willing and able instead of one crisis away from breaking. The neuroscience backs this up: Research shows that when your heart rhythm becomes coherent, your entire nervous system synchronizes. This coherent state is contagious—teams unconsciously entrain to their leader's regulated rhythm. The 30-Second Brain Reset "I don't have time for self-reflection," the startup founder insists, running on his fourth espresso. "This feels like a luxury I can't afford." This mindset is what makes everything harder. That adrenaline will take you so far, then complete burnout follows. It's like pouring kerosene on the floor and lighting a match—those burning flames make the room brighter at first, but total destruction follows. The solution is simple: Take three deep breaths plus a 30-second body scan before every team interaction. Check your heart rate. Notice tension. Feel your breathing. This simple reset activates your parasympathetic nervous system and creates space for clear thinking. The Emotional Granularity Factor "Emotional granularity" shows that people who can precisely identify their emotional states have better regulation. Instead of feeling "stressed," they recognize "frustrated with unclear expectations" or "anxious about resource allocation." This specificity creates neural pathways that bypass the amygdala's alarm response and engage the prefrontal cortex's problem-solving networks. For leaders, this means developing emotional specificity, the ability to identify, separate and regulate their responses before engaging with others' emotions. The Neuroplasticity Promise Your brain can learn new patterns at any age. Neuroplasticity research shows that consistent practice of emotional regulation literally rewires neural networks. The anterior cingulate cortex becomes more active. The prefrontal cortex develops stronger control over the amygdala. But neuroplastic change requires deliberate practice, not generic empathy training. The Contagion Choice Every leader faces a fundamental choice: Will you spread regulation or dysregulation? Your nervous system state broadcasts constantly through micro-expressions, vocal tone and body language. Your team's mirror neurons read these signals below conscious awareness. When you show up regulated, you give your team permission to regulate. When you show up anxious, you inadvertently teach them that anxiety is the appropriate response to challenges. The Real Leadership Superpower The real transformations happen when one develops genuine self-awareness; then everything else becomes possible. Leaders who couldn't connect suddenly become the most trusted on their teams. Not because they faked empathy, but because they learned to regulate first. When you stop trying to be empathetic and start learning to be aware, empathy emerges naturally. Because a regulated nervous system has the capacity for genuine connection. A dysregulated one only has the capacity for survival. Emotional regulation is an organizational strategy. Your nervous system is the most powerful leadership tool. Stop asking, "How can I be more empathetic?" Start asking, "What emotional state am I creating in this room right now?" That's not just better leadership. That's transformation. Forbes Coaches Council is an invitation-only community for leading business and career coaches. Do I qualify?


News24
7 hours ago
- News24
NGOs complain of Gaza aid deliveries blocked over ‘hostile and sometimes violent activity' rules
NGOs complained that Israel increasingly denied their requests to deliver aid to Gaza. Many aid organisations are cover for hostile activity, said Israel's Diaspora Minister Amichai Chikli. New rules on aid delivery came into effect in March. New Israeli legislation regulating foreign aid groups has been increasingly used to deny their requests to bring supplies into Gaza, according to a joint letter signed by more than 100 groups published on Thursday. Ties between foreign-backed aid groups and the Israeli government have long been beset by tensions, with officials often complaining the organisations are biased. The rocky relations have only gotten more strained in the wake of Hamas's unprecedented attack on Israel in October 2023. 'Israeli authorities have rejected requests from dozens of NGOs to bring in lifesaving goods, citing that these organisations are 'not authorised to deliver aid',' the joint statement reads. According to the letter, whose signatories include Oxfam and Doctors Without Borders (MSF), at least 60 requests to bring aid into Gaza were rejected in July alone. In March, Israel's government approved a new set of rules for foreign non-governmental organisations (NGOs) working with Palestinians. Khames Alrefi/Anadolu via Getty Images The law updates the framework for how aid groups must register to maintain their status within Israel, along with provisions that outline how their applications can be denied or registration revoked. Registration can be rejected if Israeli authorities deem that a group denies the democratic character of Israel or 'promotes delegitimisation campaigns' against the country. 'Unfortunately, many aid organisations serve as a cover for hostile and sometimes violent activity,' Israel's Diaspora Minister Amichai Chikli told AFP. #Gaza: The health care sector is experiencing a catastrophic situation. Hospitals are stretched beyond capacity. Across Gaza, hospitals are reporting 300% or higher occupancies. Hear from 5 of our colleagues share the dire situations they and their patients are facing: — Doctors Without Borders / Médecins Sans Frontières (@MSF_canada) August 13, 2025 'Organisations that have no connection to hostile or violent activity and no ties to the boycott movement will be granted permission to operate,' added Chikli, whose ministry directed an effort to produce the new guideline. Aid groups say, however, that the new rules are leaving Gazans without help. 'Our mandate is to save lives, but due to the registration restrictions civilians are being left without the food, medicine and protection they urgently need,' said Jolien Veldwijk, director of the charity CARE in the Palestinian territories. Ilia Yefimovich/picture alliance via Getty Images Veldwijk said that CARE has not been able to deliver any aid to Gaza since Israel imposed a full blockade on the Palestinian territory in March, despite partially easing it in May. Israel has long accused Hamas of stealing aid entering the Strip, and since May, the government has relied on the US-backed Gaza Humanitarian Foundation to manage food distribution centres. According to Gaza's civil defence agency, its operations have been frequently marred by chaos as thousands of Gazans have scrambled each day to approach its hubs, where some have been shot, including by Israeli soldiers.